Skip to Main Content

Paper Details

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
Neurol Res Pract
0
2023
ATE, DMG, Diffuse midline gliomas, H3, H3.1K27M, H3.3K27M, H3K27M, K27M-mutant histone-3, MHC, MHC class II, MHC-humanized rodent model, PD-L1, amino acid, antibody ATE, atezolizumab, central nervous system tumors, diffuse midline gliomas, histone-3 K27M, histone-3.3, humanized, lysine, major histocompatibility complex class II, methionine, patients, programmed death-ligand 1, pts, tumor, vac
Author NameAffiliation
Martin GlasDivision of Clinical Neurooncology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS) and West German Cancer Center, University Hospital Essen, University Duisburg-Essen
Felix SahmUniversity Hospital Heidelberg
Felix SahmClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)
Felix SahmUniversity Hospital Heidelberg
Felix SahmClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)
Andreas von DeimlingClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)
Andreas von DeimlingUniversity Hospital Heidelberg
  • 1 - 7

Datasets

Release 1.2